Headlands Technologies’s Axsome Therapeutics AXSM Stock Holding History

Headlands Technologies’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$616K	Buy	+2,517	New	+$546K	0.07%	359
2026 Q1	–	Sell	-5,187	Closed	-$947K	–	735
2025 Q4	$947K	Buy	5,187 +2,613	+102%	+$365K	0.08%	275
2025 Q3	$313K	Buy	2,574 +2,476	+2,527%	+$279K	0.03%	455
2025 Q2	$10.2K	Buy	+98	New	+$10.4K	﹤0.01%	1009
2024 Q2	–	Sell	-102	Closed	-$8.14K	–	1152
2024 Q1	$8.14K	Buy	102 +24	+31%	+$2.01K	﹤0.01%	1050
2023 Q4	$6.21K	Sell	78 -312	-80%	-$20.9K	﹤0.01%	810
2023 Q3	$27.3K	Buy	390 +65	+20%	+$4.86K	0.01%	541
2023 Q2	$23.4K	Buy	+325	New	+$24K	0.01%	546

Other funds holding AXSM

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Headlands Technologies's AXSM Position: Q2 2026 in Review

Headlands Technologies opened a new position in Axsome Therapeutics (AXSM) in Q2 2026: 2,517 shares worth $616K. The stake represents 0.07% of the portfolio and ranks #359 among its holdings. This is a return to the name: Headlands Technologies previously reported a position in AXSM as recently as Q4 2025.

Headlands Technologies first reported a position in AXSM in Q2 2023 and has held it in 8 quarters since. The position peaked at $947K in Q4 2025. 506 funds tracked by Wall St. Rank hold AXSM as of Q2 2026.

Headlands Technologies held 2,517 shares of Axsome Therapeutics worth $616K as of Q2 2026.
Axsome Therapeutics was a new Headlands Technologies position in Q2 2026.
Axsome Therapeutics made up 0.07% of Headlands Technologies's portfolio in Q2 2026, its #359 holding.
Headlands Technologies first reported a position in Axsome Therapeutics in Q2 2023 and has held it in 8 quarters since.
Headlands Technologies's Axsome Therapeutics position peaked at $947K in Q4 2025.
506 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q2 2026.

Based on Headlands Technologies's 13F filing for Q2 2026, filed 13 Aug 2026.